WO2008109560A3 - Amelioration of cellular stress response - Google Patents

Amelioration of cellular stress response Download PDF

Info

Publication number
WO2008109560A3
WO2008109560A3 PCT/US2008/055714 US2008055714W WO2008109560A3 WO 2008109560 A3 WO2008109560 A3 WO 2008109560A3 US 2008055714 W US2008055714 W US 2008055714W WO 2008109560 A3 WO2008109560 A3 WO 2008109560A3
Authority
WO
WIPO (PCT)
Prior art keywords
amelioration
stress response
cellular stress
cellular
chemotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/055714
Other languages
French (fr)
Other versions
WO2008109560A2 (en
Inventor
William Mallet
Charles Tindell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to MX2009009197A priority Critical patent/MX2009009197A/en
Priority to AU2008222926A priority patent/AU2008222926A1/en
Priority to EP08731289A priority patent/EP2118133A2/en
Priority to CN200880014513A priority patent/CN101790539A/en
Priority to CA002678555A priority patent/CA2678555A1/en
Priority to JP2009551894A priority patent/JP2010521425A/en
Publication of WO2008109560A2 publication Critical patent/WO2008109560A2/en
Publication of WO2008109560A3 publication Critical patent/WO2008109560A3/en
Priority to IL200483A priority patent/IL200483A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to compositions and methods useful for treating cancer and for amelioration of cellular stress response triggered by chemotherapy.
PCT/US2008/055714 2007-03-02 2008-03-03 Amelioration of cellular stress response Ceased WO2008109560A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MX2009009197A MX2009009197A (en) 2007-03-02 2008-03-03 Amelioration of cellular stress response.
AU2008222926A AU2008222926A1 (en) 2007-03-02 2008-03-03 Amelioration of cellular stress response
EP08731289A EP2118133A2 (en) 2007-03-02 2008-03-03 Amelioration of cellular stress response
CN200880014513A CN101790539A (en) 2007-03-02 2008-03-03 Alleviation of cellular stress response
CA002678555A CA2678555A1 (en) 2007-03-02 2008-03-03 Amelioration of cellular stress response
JP2009551894A JP2010521425A (en) 2007-03-02 2008-03-03 Improvement of cellular stress response
IL200483A IL200483A0 (en) 2007-03-02 2009-08-19 Amelioration of cellular stress response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89280607P 2007-03-02 2007-03-02
US60/892,806 2007-03-02

Publications (2)

Publication Number Publication Date
WO2008109560A2 WO2008109560A2 (en) 2008-09-12
WO2008109560A3 true WO2008109560A3 (en) 2008-12-11

Family

ID=39532129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055714 Ceased WO2008109560A2 (en) 2007-03-02 2008-03-03 Amelioration of cellular stress response

Country Status (8)

Country Link
EP (1) EP2118133A2 (en)
JP (1) JP2010521425A (en)
CN (1) CN101790539A (en)
AU (1) AU2008222926A1 (en)
CA (1) CA2678555A1 (en)
IL (1) IL200483A0 (en)
MX (1) MX2009009197A (en)
WO (1) WO2008109560A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017520A1 (en) * 2009-08-05 2011-02-10 Wake Forest University Health Sciences Compositions and methods for inducing apoptosis in prostate cancer cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790631B1 (en) * 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790631B1 (en) * 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"AKT as a target for enhancing breast cancer chemotherapy and radiotherapy", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, 1 November 2002 (2002-11-01), pages S159, XP004403977, ISSN: 0959-8049 *
CHINNAIYAN ET AL: "Radiation and New Molecular Agents, Part II: Targeting HDAC, HSP90, IGF-1R, PI3K, and Ras", SEMINARS IN RADIATION ONCOLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 16, no. 1, 1 January 2006 (2006-01-01), pages 59 - 64, XP005219363, ISSN: 1053-4296 *
FUHRMAN C B ET AL: "Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 110, no. 1, 1 July 2008 (2008-07-01), pages 93 - 98, XP022795065, ISSN: 0090-8258, [retrieved on 20080625] *
MUSCELLA ET AL: "Differential response of normal, dedifferentiated and transformed thyroid cell lines to cisplatin treatment", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 71, no. 1-2, 19 December 2005 (2005-12-19), pages 50 - 60, XP005191196, ISSN: 0006-2952 *
RAMING K ET AL: "Identification of a novel G-protein coupled receptor expressed in distinct brain regions and a defined olfactory zone", RECEPTORS AND CHANNELS, HARWOOD ACADEMIC PUBLISHERS, CH, vol. 6, no. 2, 1 January 1998 (1998-01-01), pages 141 - 151, XP000925988, ISSN: 1060-6823 *
TANEL ET AL: "P38 and ERK mitogen-activated protein kinases mediate acrolein-induced apoptosis in Chinese hamster ovary cells", CELLULAR SIGNALLING, ELSEVIER SCIENCE LTD, GB, vol. 19, no. 5, 23 March 2007 (2007-03-23), pages 968 - 977, XP005934431, ISSN: 0898-6568 *
XIA C ET AL: "Identification of a prostate-specific G-protein coupled receptor in prostate cancer.", ONCOGENE 13 SEP 2001, vol. 20, no. 41, 13 September 2001 (2001-09-13), pages 5903 - 5907, XP002499946, ISSN: 0950-9232 *
XU L L ET AL: "PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, USA, DE, vol. 60, no. 23, 1 December 2000 (2000-12-01), pages 6568 - 6572, XP002290228 *
YOUNG D A ET AL: "mTOR - beyond transplantation", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 5, no. 4, 1 August 2005 (2005-08-01), pages 418 - 423, XP004969010, ISSN: 1471-4892 *
YUAN T T-T ET AL: "Cloning and genetic characterization of an evolutionarily conserved human olfactory receptor that is differentially expressed across species", GENE, ELSEVIER, AMSTERDAM, NL, vol. 278, no. 1-2, 31 October 2001 (2001-10-31), pages 41 - 51, XP004322240, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
JP2010521425A (en) 2010-06-24
EP2118133A2 (en) 2009-11-18
CN101790539A (en) 2010-07-28
IL200483A0 (en) 2010-04-29
WO2008109560A2 (en) 2008-09-12
AU2008222926A1 (en) 2008-09-12
MX2009009197A (en) 2009-09-04
CA2678555A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
WO2011083088A3 (en) Methods for treating colorectal cancer
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
WO2008019124A8 (en) Heteroaryl compounds useful as inhibitors of e1 activating enzymes
WO2009111676A3 (en) Boron-containing small molecules as anti-inflammatory agents
WO2014007951A3 (en) Substituted tricyclic compounds as fgfr inhibitors
WO2012058211A3 (en) Quinazoline derivatives, compositions, and uses related thereto
WO2007054623A3 (en) Mammalian hedgehog signaling inhiabitors
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
JO2778B1 (en) Certain vehicles, installations and methods
WO2011083090A3 (en) Methods for treating breast cancer
WO2013163190A8 (en) Dna-pk inhibitors
MX343042B (en) Bicyclic heteroaryl compounds.
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
GEP20156266B (en) Spiroheterocyclic n-oxypiperidines as pesticides
JO2761B1 (en) 1Phenyl-2-Pyridinyl Alkyl Alcohol Derivatives As Phosphodiesterase Inhibitors
WO2009064486A3 (en) Inhibitors of pim protein kinases, compositions, and methods for treating cancer
MX2012007507A (en) Heteroaryl compounds and uses thereof.
IL211541A0 (en) Co-crystal compositions, methods of producing the same and uses thereof
WO2012099930A3 (en) Flavonol compositions
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2010068292A8 (en) Azaindole derivatives as kinase inhibitors
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
AU2007249926A8 (en) Monocyclic heteroaryl compounds
WO2013112699A3 (en) Proteasome activity enhancing compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880014513.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731289

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 579064

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2678555

Country of ref document: CA

Ref document number: 5267/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008222926

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200483

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008731289

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/009197

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009551894

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008222926

Country of ref document: AU

Date of ref document: 20080303

Kind code of ref document: A